Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 90 days

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jun 24, 2023 9:01pm

235 Views

Post# 35513254

RE:90 days

@westcoast1000. I refer you to the news release March 21, 2022. There were two mCRC cohorts and one anal. Cohort 4 anal did not require a safety run-in nor did Cohort 2 first-line MSImCRC, but Cohort 3, third-line mCRC did. It is an interestimg release, and may be the key to the endgame.

I think last weeks news gave us numerous avenues; credit to those involved.

Cheers

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta